UB Paderborn / Katalog / Suche / in CDI

A retrospective analysis of 3954 patients in phase 2/3 trials of bortezomib for the treatment of multiple myeloma: towards providing a benchmark for the cardiac safety profile of proteasome inhibition in multiple myeloma

British journal of haematology, 2017-08, Vol.178 (4), p.547-560

2017

Volltextzugriff (PDF)

Effect of cumulative bortezomib dose on survival in multiple myeloma patients receiving bortezomib‐melphalan‐prednisone in the phase III VISTA study

American journal of hematology, 2015-04, Vol.90 (4), p.314-319

2015

Volltextzugriff (PDF)

Long-term efficacy and safety of celecoxib in Alzheimer's disease

Dementia and geriatric cognitive disorders, 2007-01, Vol.23 (1), p.8

2007

Volltextzugriff (PDF)

Pooled analysis of GI tolerability of 21 randomized controlled trials of celecoxib and nonselective NSAIDs

Current medical research and opinion, 2009-03, Vol.25 (3), p.729-740

2009

Volltextzugriff (PDF)

The challenge of cross-trial comparisons using limited data

Haematologica (Roma), 2014-08, Vol.99 (8), p.e145

2014

Volltextzugriff (PDF)

Burden of anemia in patients with osteoarthritis and rheumatoid arthritis in French secondary care

BMC geriatrics, 2010-08, Vol.10 (1), p.59-59, Article 59

2010

Volltextzugriff (PDF)

Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma

The New England journal of medicine, 2016-04, Vol.374 (17), p.1621-1634

2016

Volltextzugriff (PDF)

Community-Based Phase IIIB Trial of Three UPFRONT Bortezomib-Based Myeloma Regimens

Journal of clinical oncology, 2015-11, Vol.33 (33), p.3921-3929

2015

Volltextzugriff (PDF)

Cardiovascular events among 1090 cancer patients treated with sunitinib, interferon, or placebo: A comprehensive adjudicated database analysis demonstrating clinically meaningful reversibility of cardiac events

European journal of cancer (1990), 2014-08, Vol.50 (12), p.2162-2170

2014

Volltextzugriff (PDF)

A phase 1 trial of the bifunctional EGFR/TGFβ fusion protein BCA101 alone and in combination with pembrolizumab in patients with advanced solid tumors

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.2513-2513

2022

Volltextzugriff (PDF)

Comparative Effectiveness Research on the Treatment Outcomes of Subcutaneous (SC) and Intravenous (IV) Bortezomib (BTZ) in Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts)

Blood, 2015-12, Vol.126 (23), p.4506-4506

2015

Volltextzugriff (PDF)

Abstract 6677: Preliminary immune correlatives from BCA101 trial show favorable modulation of tumor immune microenvironment

Cancer research (Chicago, Ill.), 2023-04, Vol.83 (7_Supplement), p.6677-6677

2023

Volltextzugriff (PDF)

Tourmaline US-MM6, an Open-Label, Single-Arm, Multicenter Study Evaluating the Effectiveness and Safety of Ixazomib in Combination with Lenalidomide and Dexamethasone (IRd) in Patients (pts) with Newly Diagnosed Multiple Myeloma (NDMM) Switching from a Bortezomib-Based Triplet Induction Regimen

Blood, 2017-12, Vol.130, p.5407-5407

2017

Volltextzugriff (PDF)

Treatment patterns and outcomes with subcutaneous bortezomib in patients with relapsed mantle cell lymphoma: a retrospective, observational study of patient medical records from US community oncology practices

Leukemia & lymphoma, 2017-08, Vol.58 (8), p.1968-1972

2017

Volltextzugriff (PDF)

Meta-Analysis of the Efficacy and Safety of Bortezomib Re-Treatment in Patients With Multiple Myeloma

Clinical lymphoma, myeloma and leukemia, 2014-10, Vol.14 (5), p.380-388

2014

Volltextzugriff (PDF)

Impact Of Route Of Bortezomib (B) Administration On Dose Intensity and Time To Dose Reduction In Previously Untreated Patients (Pts) With Multiple Myeloma (MM)

Blood, 2013-11, Vol.122 (21), p.1941-1941

2013

Volltextzugriff (PDF)

Integrated Safety Analysis of Single-Agent MLN8237 (alisertib), an Investigational Aurora A Kinase Inhibitor, in Patients with Advanced Hematologic Malignancies and Solid Tumors

Blood, 2012-11, Vol.120 (21), p.3683-3683

2012

Volltextzugriff (PDF)

Scrotal Cutaneous Side Effects of Sunitinib

The New England journal of medicine, 2008-08, Vol.359 (9), p.975-976

2008

Volltextzugriff (PDF)

Retrospective analysis of treatment patterns and outcomes with subcutaneous (SQ) bortezomib (BTZ) in patients (pts) with relapsed mantle cell lymphoma (MCL)

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.8554-8554

2014

Volltextzugriff (PDF)

Efficacy and Safety Of Three Bortezomib-Based Induction and Maintenance Regimens In Previously Untreated, Transplant-Ineligible Multiple Myeloma (MM) Patients (Pts): Final Results From The Randomized, Phase 3b, US Community-Based UPFRONT Study (NCT00507416)

Blood, 2013-11, Vol.122 (21), p.1966-1966

2013

Volltextzugriff (PDF)

Higher Cumulative Bortezomib Dose Results In Better Overall Survival (OS) In Patients With Previously Untreated Multiple Myeloma (MM) Receiving Bortezomib-Melphalan-Prednisone (VMP) In The Phase 3 VISTA Study

Blood, 2013-11, Vol.122 (21), p.1968-1968

2013

Volltextzugriff (PDF)

Subcutaneous (SQ) Bortezomib (BTZ) in Patients (Pts) with Relapsed Mantle Cell Lymphoma (MCL): Retrospective, Observational Study of Treatment Patterns and Outcomes in US Community Oncology Practices

Blood, 2014-12, Vol.124 (21), p.1740-1740

2014

Volltextzugriff (PDF)

Sunitinib objective response (OR) in metastatic renal cell carcinoma (mRCC): Analysis of 1,059 patients treated on clinical trials

Journal of clinical oncology, 2012-05, Vol.30 (15_suppl), p.4542-4542

2012

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

A retrospective analysis of 3954 patients in phase 2/3 trials of bortezomib for the treatment of multiple myeloma: towards providing a benchmark for the cardiac safety profile of proteasome inhibition in multiple myeloma

Effect of cumulative bortezomib dose on survival in multiple myeloma patients receiving bortezomib‐melphalan‐prednisone in the phase III VISTA study

Long-term efficacy and safety of celecoxib in Alzheimer's disease

Pooled analysis of GI tolerability of 21 randomized controlled trials of celecoxib and nonselective NSAIDs

The challenge of cross-trial comparisons using limited data

Burden of anemia in patients with osteoarthritis and rheumatoid arthritis in French secondary care

Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma

Community-Based Phase IIIB Trial of Three UPFRONT Bortezomib-Based Myeloma Regimens

Cardiovascular events among 1090 cancer patients treated with sunitinib, interferon, or placebo: A comprehensive adjudicated database analysis demonstrating clinically meaningful reversibility of cardiac events

A phase 1 trial of the bifunctional EGFR/TGFβ fusion protein BCA101 alone and in combination with pembrolizumab in patients with advanced solid tumors

Comparative Effectiveness Research on the Treatment Outcomes of Subcutaneous (SC) and Intravenous (IV) Bortezomib (BTZ) in Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts)

Abstract 6677: Preliminary immune correlatives from BCA101 trial show favorable modulation of tumor immune microenvironment

Tourmaline US-MM6, an Open-Label, Single-Arm, Multicenter Study Evaluating the Effectiveness and Safety of Ixazomib in Combination with Lenalidomide and Dexamethasone (IRd) in Patients (pts) with Newly Diagnosed Multiple Myeloma (NDMM) Switching from a Bortezomib-Based Triplet Induction Regimen

Treatment patterns and outcomes with subcutaneous bortezomib in patients with relapsed mantle cell lymphoma: a retrospective, observational study of patient medical records from US community oncology practices

Meta-Analysis of the Efficacy and Safety of Bortezomib Re-Treatment in Patients With Multiple Myeloma

Uncovering the Blind Spot of Clinical Trials: First Report of Baseline Characteristics of Newly Diagnosed (ND) and Relapsed/Refractory (RR) Multiple Myeloma (MM) Patients (Pts) in Insight-MM, a Global, Prospective, Observational Study

Impact Of Route Of Bortezomib (B) Administration On Dose Intensity and Time To Dose Reduction In Previously Untreated Patients (Pts) With Multiple Myeloma (MM)

Integrated Safety Analysis of Single-Agent MLN8237 (alisertib), an Investigational Aurora A Kinase Inhibitor, in Patients with Advanced Hematologic Malignancies and Solid Tumors

Scrotal Cutaneous Side Effects of Sunitinib

Retrospective analysis of treatment patterns and outcomes with subcutaneous (SQ) bortezomib (BTZ) in patients (pts) with relapsed mantle cell lymphoma (MCL)

Global, Prospective, Non-Interventional, Observational Study of Presentation, Treatment Patterns, and Outcomes in Multiple Myeloma Patients: The Insight-MM Study

Efficacy and Safety Of Three Bortezomib-Based Induction and Maintenance Regimens In Previously Untreated, Transplant-Ineligible Multiple Myeloma (MM) Patients (Pts): Final Results From The Randomized, Phase 3b, US Community-Based UPFRONT Study (NCT00507416)

Higher Cumulative Bortezomib Dose Results In Better Overall Survival (OS) In Patients With Previously Untreated Multiple Myeloma (MM) Receiving Bortezomib-Melphalan-Prednisone (VMP) In The Phase 3 VISTA Study

Subcutaneous (SQ) Bortezomib (BTZ) in Patients (Pts) with Relapsed Mantle Cell Lymphoma (MCL): Retrospective, Observational Study of Treatment Patterns and Outcomes in US Community Oncology Practices

Sunitinib objective response (OR) in metastatic renal cell carcinoma (mRCC): Analysis of 1,059 patients treated on clinical trials

Suchergebnisse filtern